Apexigen Inc. announced the initiation of patient enrollment in a phase II trial in collaboration with the University of California San Francisco. The trial is designed to evaluate Apexigen's CD40 agonistic antibody, APX-005M, in combination with chemotherapy and radiation therapy in patients with resectable esophageal and gastro-esophageal junction cancers.